ADReCS

Pharmaceutical Information

Drug Name	Raltegravir
Drug ID	BADD_D01905
Description	Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage	For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status	approved
ATC Code	J05AJ01
DrugBank ID	DB06817
KEGG ID	D06676
MeSH ID	D000068898
PubChem ID	54671008
TTD Drug ID	D0I1FQ
NDC Product Code	0006-0477; 0006-3603; 50090-1085; 65977-0049; 82982-055; 17381-749; 0006-0227; 53002-1686; 71205-777; 68071-2113; 0006-3080; 0006-0473
UNII	22VKV8053U
Synonyms	Raltegravir Potassium \| Potassium, Raltegravir \| Raltegravir \| MK 0518 \| 0518, MK \| MK0518 \| MK-0518 \| Isentress

Chemical Information

Molecular Formula	C20H21FN6O5
CAS Registry Number	518048-05-0
SMILES	CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Respiratory distress	22.02.01.012	0.002472%		Not Available
Respiratory failure	14.01.04.003; 22.02.06.002	0.002472%
Rhabdomyolysis	15.05.05.002	0.006922%
Rhinorrhoea	22.12.03.021	0.005274%
Shock	24.06.02.002	0.001648%		Not Available
Skin exfoliation	23.03.07.003	0.003626%		Not Available
Splenomegaly	01.09.02.001	0.001648%		Not Available
Stevens-Johnson syndrome	10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005	0.001648%
Stillbirth	08.04.01.006; 18.01.02.002	0.003296%		Not Available
Suicidal ideation	19.12.01.003	0.006592%
Syncope	02.11.04.015; 24.06.02.012; 17.02.04.008	0.003296%
Thrombocytopenia	01.08.01.002	0.007416%		Not Available
Thrombotic thrombocytopenic purpura	24.07.06.014; 23.06.01.011; 01.08.01.005	0.001648%
Uterine leiomyoma	21.07.02.004; 16.04.02.001	0.001648%		Not Available
Vomiting	07.01.07.003	0.032138%
Energy increased	08.01.03.017	0.005604%		Not Available
Ischaemic cardiomyopathy	24.04.04.019; 02.04.01.004	0.002472%		Not Available
Retinal toxicity	12.03.01.036; 06.09.03.013	0.001648%		Not Available
Lipodystrophy acquired	23.07.01.003; 14.08.04.008	0.002472%		Not Available
General physical health deterioration	08.01.03.018	0.002472%		Not Available
Muscle tightness	15.05.03.007	0.003626%		Not Available
Musculoskeletal stiffness	15.03.05.027	0.003626%		Not Available
Foetal death	18.01.02.003; 08.04.01.011	0.004120%
Toxic skin eruption	12.03.01.073; 23.03.05.003; 10.01.01.008	0.003296%		Not Available
Lung neoplasm malignant	22.08.01.001; 16.19.02.001	0.001648%		Not Available
Drug resistance	08.06.01.005	0.010218%		Not Available
Adverse event	08.06.01.010	0.043015%		Not Available
Feeding disorder	19.09.01.003; 14.03.02.003	0.001648%		Not Available
Inflammation	10.02.01.089; 08.01.05.007	0.001648%		Not Available
Abnormal behaviour	19.01.01.001	0.001648%		Not Available

The 4th Page First Pre 4 5 6 Next Last Total 6 Pages